Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. Today, we learn about how scientists had a happenstance discovery about tumor-suppressor genes and used them to target aggressive pediatric tumor cells. We see a U.K. health agency make a controversial call about an ALS drug made by Biogen, and more.
The need-to-know this morning
- Biogen and Eisai‘s FDA application for a subcutaneous version of the Alzheimer’s drug Leqembi has been delayed. The FDA has asked for three months of immunogenicity data and a Fast Track designation-specific application.
A genetic clue to suppressing a fatal childhood tumor
Most cancers are able to proliferate because the “tumor suppressor” genes meant to keep cell growth in check are dysfunctional. But researchers recently chanced upon a way to treat these sorts of cancers, focusing in vitro on a rare and aggressive childhood cancer called rhabdoid tumors. Researchers were able to fix a broken tumor suppressor system, turning malignant cells back into ordinary ones. The approach is still far from clinical trials, but offers a new pathway for scientists to target hard-to-treat cancers.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect